Tectonic reports Q4 2024 net loss $12.4M; positive TX45 Phase 1b interim results

Tectonic Therapeutic, Inc.

TX45 Phase 1b Part A reduced PCWP by 17.9% in PH-HFpEF and PVR >30% in CpcPH subgroup.
Completed ~$185.0M private placement in Feb 2025; cash runway into Q4'28.
Cash and equivalents $141.2M at Dec 31, 2024; Q4 net loss $12.4M vs $7.9M year ago.
APEX Phase 2 trial topline results expected in 2026; Phase 1b Part B results expected 2H'25.
TX2100 Phase 1 initiation expected Q4'25 or Q1'26 for hereditary hemorrhagic telangiectasia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.